细胞生物学
泛素
BRD4
蛋白质降解
信号转导
染色质
化学
蛋白酶体
生物
生物化学
组蛋白
溴尿嘧啶
DNA
基因
作者
Mori Yuki,Yoshino Akizuki,Rikuto Honda,Miyu Takao,Ayaka Tsuchimoto,Sota Hashimoto,H. Iio,Masakazu Kato,Ai Kaiho-Soma,Yasushi Saeki,Jun Hamazaki,Shigeo Murata,Toshikazu Ushijima,Naoko Hattori,Fumiaki Ohtake
标识
DOI:10.1038/s41467-024-49519-z
摘要
Abstract Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2 VHL - or CRL4 CRBN -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib). Mechanistically, PARG inhibition promotes TRIP12-mediated K29/K48-linked branched ubiquitylation of BRD4 by facilitating chromatin dissociation of BRD4 and formation of the BRD4–PROTAC–CRL2 VHL ternary complex; by contrast, HSP90 inhibition promotes BRD4 degradation after the ubiquitylation step. Consequently, these signal inhibitors sensitize cells to the PROTAC-induced apoptosis. These results suggest that various cell-intrinsic signaling pathways spontaneously counteract chemically induced target degradation at multiple steps, which could be liberated by specific inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI